Arip MT (Abilify)5mg – 150 pill

Arip MT (Abilify)5mg – 150 pill

$42.91

Each arip MT contains 5 mg of Aripiprazole with 150 tablets per box treats psychotic conditions such as schizophrenia, tourette’s disorder, bipolar.

ATC Classification: N05AX12
Active Ingrediant: Aripiprazole
Generic Name: Arip MT
Manufacturer: Torrent Pharma
Strength: 5mg
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 150 Tab

Description

What is this drug used for?

• It is used to treat schizophrenia.

• It is used to treat bipolar problems.

• It is used to treat low mood (depression).

• It is used to treat certain behavior problems in patients with autism.

• It is used to treat Tourette’s syndrome.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Fatigue

• Agitation

• Anxiety

• Headache

• Nausea

• Vomiting

• Weight gain

• Constipation

• Trouble sleeping

• Change in appetite

• Lack of appetite

• Stuffy nose

• Sore throat

• Dry mouth

• Tremors

• Drooling

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Infection

• Depression like thoughts of suicide, anxiety, emotional instability, or confusion.

• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit.

• Abnormal movements

• Twitching

• Change in balance

• Difficulty swallowing

• Vision changes

• Eye pain

• Eye irritation

• Difficulty speaking

• Severe dizziness

• Passing out

• Loss of strength and energy

• Blurred vision

• Uncontrollable urges

• Neuroleptic malignant syndrome like fever, muscle cramps or stiffness, dizziness, severe headache, confusion, change in thinking, fast heartbeat, abnormal heartbeat, or sweating a lot.

• Tardive dyskinesia like unable to control body movements; tongue, face, mouth, or jaw sticking out; mouth puckering; or puffing cheeks.

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

 

Pronunciation

(ay ri PIP ray zole)

 

Medication Safety Issues

Sound-alike/look-alike issues:

Abilify may be confused with Ambien

ARIPiprazole may be confused with proton pump inhibitors (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, RABEprazole)

Geriatric Patients: High-Risk Medication:

Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of cerebrovascular accidents (stroke) and a greater rate of cognitive decline and mortality in patients with dementia. Use may be appropriate in geriatric patients with schizophrenia, bipolar disorder, other mental health conditions, or for short-term use as an antiemetic during chemotherapy, but should be given in the lowest effective dose for the shortest duration possible. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2019]).

Other safety issues:

There are two ER formulations available for IM administration: Aripiprazole monohydrate (Abilify Maintena) and aripiprazole lauroxil (Aristada and Aristada Initio)

 

Product Availability (US)

Abilify immediate-release injection (9.75 mg/1.3 mL) has been discontinued in the US for more than 1 year.

 

Storage/Stability

Injection, powder (extended release):

Prefilled syringe: Store below 30°C (86°F). Do not freeze. Protect from light and store in original package.

Vial for reconstitution: Store unused vials at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). If the suspension is not administered immediately after reconstitution, store at room temperature in the vial (do not store in a syringe).

Oral solution and tablets: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Use oral solution within 6 months after opening. Do not store in conditions where tablets are exposed to humid conditions.

Mycite Patch: Store at 15°C to 30°C (59°F to 86°F); 15% to 93% relative humidity.

 

Adverse Reactions

IM:

Cardiovascular: Anxiety, tachycardia

Central nervous system: Akathisia (dose-related), dizziness, drowsiness, dystonia, extrapyramidal reaction, fatigue (dose-related), headache, insomnia, restlessness, sedation

Endocrine & metabolic: Decreased HDL cholesterol, increased LDL cholesterol, increased serum cholesterol, increased serum glucose, increased serum triglycerides, weight gain, weight loss

Gastrointestinal: Constipation, diarrhea, vomiting, xerostomia

Hematologic & oncologic: Neutropenia

Local: Injection site reaction (including erythema, induration, inflammation, hemorrhage, pruritus, rash, swelling), pain at injection site

Neuromuscular & skeletal: Arthralgia, back pain, musculoskeletal pain, myalgia, tremor (dose-related)

Respiratory: Nasal congestion, upper respiratory tract infection

Oral:

Cardiovascular: Orthostatic hypotension

Central nervous system: Agitation, akathisia (dose-related; more common in adults), anxiety, dizziness, drooling (children and adolescents), drowsiness (more common in children and adolescents), dystonia, extrapyramidal reaction (dose-related; more common in children and adolescents), fatigue (dose-related; more common in children and adolescents), headache (more common in adults), insomnia, irritability (children and adolescents), lethargy (older adults and children), pain, restlessness, sedation (dose-related; more common in children and adolescents)

Dermatologic: Skin rash

Endocrine & metabolic: Decreased HDL cholesterol (children and adolescents), increased serum cholesterol, increased serum glucose (more common in adults), increased serum triglycerides, weight gain (more common in children and adolescents), weight loss

Gastrointestinal: Abdominal distress, anorexia, constipation (more common in adults), decreased appetite (children and adolescents), diarrhea (children and adolescents), dyspepsia, increased appetite (children and adolescents), nausea, stomach discomfort, toothache, upper abdominal pain (children and adolescents), vomiting, xerostomia

Genitourinary: Urinary incontinence (older adults)

Local: Application site rash (Mycite patch)

Neuromuscular & skeletal: Arthralgia, asthenia (children and adolescents), limb pain, muscle rigidity (children and adolescents), muscle spasm, myalgia, stiffness, tremor (dose-related)

Ophthalmic: Blurred vision

Respiratory: Cough, epistaxis (children and adolescents), nasopharyngitis (children and adolescents), pharyngolaryngeal pain

Miscellaneous: Fever (children and adolescents)

Rare but important or life-threatening: Abdominal distress (injection), abnormal bilirubin levels, abnormal gait, abnormal hepatic function tests, abnormal T waves on ECG, aggressive behavior, agitation (injection), agranulocytosis, akinesia, alopecia, altered serum glucose, amenorrhea, anaphylaxis, angina pectoris, angioedema, anorexia (injection), anorgasmia, aspiration pneumonia, asthenia (injection), ataxia, atrial fibrillation, atrial flutter, atrioventricular block, blurred vision (injection), bradycardia, bradykinesia, bruxism, cardiac arrhythmia, catatonia, cerebrovascular accident, change in libido, chest discomfort, chest pain, choreoathetosis, cogwheel rigidity, decreased appetite (injection), decreased serum cholesterol, decreased serum triglycerides, delayed ejaculation, delirium, depression, diabetes mellitus, diabetic ketoacidosis, diplopia, disruption of body temperature regulation, dysgeusia, dyspepsia (injection), dysphagia, dyspnea, dystonia (oromandibular), edema, elevated glycosylated hemoglobin, erectile dysfunction, esophagitis, extrasystoles, eyelid edema, facial edema, falling, fever (injection), gastroesophageal reflux disease, glycosuria, gynecomastia, heatstroke, hepatic failure, hepatitis, hepatotoxicity, hirsutism, homicidal ideation, hostility, hyperglycemia, hyperhidrosis, hyperinsulinism, hyperlipidemia, hypersensitivity reaction, hypersomnia, hypertension, hypertonia, hypoglycemia, hypokalemia, hypokinesia, hyponatremia, hypotension (oral), hypothermia, hypotonia, impulse control disorder (including pathologic gambling and hypersexuality), increased blood urea nitrogen, increased creatinine clearance, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased liver enzymes, increased serum bilirubin, increased serum prolactin, inhibition of prolactin secretion, intentional injury, irritability (injection), ischemic heart disease, jaundice, joint stiffness, laryngospasm, lethargy (injection), leukopenia, limb pain (injection), mastalgia, memory impairment, menstrual disease, mobility disorder, muscle rigidity (injection), muscle spasm (injection), muscle twitching, myasthenia, myocardial infarction, myoclonus, nasal congestion (oral), nasopharyngitis (injection), nausea (injection), neuroleptic malignant syndrome, nocturia, obesity, oculogyric crisis, oropharyngeal spasm, pain (oral), palpitations, pancreatitis, panic attack, Parkinson disease, peripheral edema, pharyngolaryngeal pain (injection), photophobia, photopsia, pollakiuria, polydipsia, polyuria, presyncope, priapism, prolonged Q-T interval on ECG, pruritus, psychosis, rhabdomyolysis, seizure (including injection), seizure (tonic clonic), sinus tachycardia, skin photosensitivity, skin rash (injection), sleep apnea (obstructive) (Health Canada, August 16, 2016; Shirani 2011), sleep talking, somnambulism, speech disturbance, stomach discomfort (injection), suicidal ideation, suicidal tendencies, supraventricular tachycardia, swollen tongue, syncope, tardive dyskinesia, thrombocytopenia, tics, tongue spasm, toothache (injection), torsades de pointes, transient ischemic attacks, trismus, uncontrolled diabetes mellitus, upper abdominal pain (injection), urinary incontinence (injection), urinary r

Brand

Torrent Pharma

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Reviews

There are no reviews yet.

Be the first to review “Arip MT (Abilify)5mg – 150 pill”

Your email address will not be published.